Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, review timing and choice of first-line antiretroviral therapy in this unique program with a didactic video module and several case-based vignettes in which you are invited to help manage the patient.
Upon completion of this activity, participants should be able to:
Clinical Impact of Data From the 2015 Conference on Retroviruses and Opportunistic Infections
HIV Seattle Update
The Availability of Coformulated Cobicistat-Boosted Protease Inhibitors and the Impact on My Practice
More Favorable Renal and Bone Safety Profile With TAF vs TDF When Coformulated in Single-Tablet Regimen With EVG/COBI/FTC in Treatment-Naive Patients
ION-4: 96% SVR Rate With LDV/SOF for 12 Weeks in Patients Coinfected With HIV and Genotype 1 or 4 HCV
Clinical Care Options, LLC. All Rights Reserved.